The advent of antiangiogenic therapy (AAT), inspired by Folkman’s hypothesis postulating that tumors rely on angiogenesis (5), has revolutionized the management of CRC by targeting the vascular endothelial growth factor (VEGF) and its receptor (VEGFR) axis, which are pivotal for tumor angiogenesis and progression (6–8). Here, VEGFA is linked to neoplasm.